Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02041533
Title	An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Bristol-Myers Squibb
Indications	lung non-small cell carcinoma
Therapies	Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine
Age Groups:	adult
Covered Countries	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS